Trial Outcomes & Findings for Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip (NCT NCT03985839)
NCT ID: NCT03985839
Last Updated: 2026-07-13
Results Overview
Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.
COMPLETED
298 participants
6 months
2026-07-13
Participant Flow
One Participant was excluded because the study device could not be used intraoperatively due to anchor failure.
Participant milestones
| Measure |
MICRORAPTOR™ REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Overall Study
STARTED
|
114
|
122
|
61
|
|
Overall Study
COMPLETED
|
79
|
75
|
43
|
|
Overall Study
NOT COMPLETED
|
35
|
47
|
18
|
Reasons for withdrawal
| Measure |
MICRORAPTOR™ REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Overall Study
Lost to Follow-up
|
28
|
35
|
14
|
|
Overall Study
Adverse Event
|
2
|
1
|
0
|
|
Overall Study
Physician Decision
|
1
|
2
|
1
|
|
Overall Study
Withdrawal by Subject
|
2
|
8
|
2
|
|
Overall Study
Non-compliance with Follow-up Visits
|
1
|
0
|
0
|
|
Overall Study
Subject Relocated
|
0
|
0
|
1
|
|
Overall Study
Device Deficiency
|
1
|
0
|
0
|
|
Overall Study
Follow-up Visit Missed and Could Not be Rescheduled
|
0
|
1
|
0
|
Baseline Characteristics
Safety and Performance of MICRORAPTOR™ Suture Anchors in Shoulder and Hip
Baseline characteristics by cohort
| Measure |
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=114 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=122 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=61 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
Total
n=297 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
40.80 years
STANDARD_DEVIATION 13.64 • n=20 Participants
|
41.88 years
STANDARD_DEVIATION 14.94 • n=20 Participants
|
40.16 years
STANDARD_DEVIATION 15.17 • n=40 Participants
|
41.12 years
STANDARD_DEVIATION 14.44 • n=5 Participants
|
|
Sex: Female, Male
Female
|
68 Participants
n=20 Participants
|
65 Participants
n=20 Participants
|
32 Participants
n=40 Participants
|
165 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
46 Participants
n=20 Participants
|
57 Participants
n=20 Participants
|
29 Participants
n=40 Participants
|
132 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
6 Participants
n=20 Participants
|
5 Participants
n=20 Participants
|
6 Participants
n=40 Participants
|
17 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
99 Participants
n=20 Participants
|
115 Participants
n=20 Participants
|
55 Participants
n=40 Participants
|
269 Participants
n=5 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
9 Participants
n=20 Participants
|
2 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
11 Participants
n=5 Participants
|
|
Region of Enrollment
United States
|
114 Participants
n=20 Participants
|
122 Participants
n=20 Participants
|
61 Participants
n=40 Participants
|
297 Participants
n=5 Participants
|
|
Body Mass Index (BMI)
|
26.44 kg/m^2
STANDARD_DEVIATION 4.85 • n=20 Participants
|
28.63 kg/m^2
STANDARD_DEVIATION 5.67 • n=20 Participants
|
27.32 kg/m^2
STANDARD_DEVIATION 5.05 • n=40 Participants
|
27.52 kg/m^2
STANDARD_DEVIATION 5.31 • n=5 Participants
|
PRIMARY outcome
Timeframe: 6 monthsPopulation: The Safety (SAF) Population included all participants that received the specified study device with data collected for the outcome and time frame indicated.
Repair failure at 6 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 6-month follow-up.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=108 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=84 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=44 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Repair Failure Rate at 6 Months
|
0.93 proportion of participants
|
0 proportion of participants
Interval 95.7 to 100.0
|
0 proportion of participants
|
SECONDARY outcome
Timeframe: 12 monthsPopulation: The Safety (SAF) Population included all participants that received the specified study device with data collected for the outcome and time frame indicated.
Repair failure at 12 months was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 12-month follow-up.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=91 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=84 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=43 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Repair Failure Rate at 12 Months
|
0 proportion of participants
|
0 proportion of participants
|
0 proportion of participants
|
SECONDARY outcome
Timeframe: Baseline to 6 months, 12 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included all participants enrolled into the study and had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).
Pain was assessed using a Visual Analogue Scale (VAS) where participants indicated their pain level by marking a point that represented their perceived pain intensity. Scores ranged from 0 to 100, with 0 representing no pain and 100 representing the worst imaginable pain (i.e., a worse outcome). A decrease in VAS Pain score indicated a reduction in pain (i.e., a better outcome) and an increase indicated worsening in pain (i.e., a worse outcome). The mean change in pain score was recorded on the VAS from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=104 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=82 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=44 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Visual Analogue Scale (VAS) Pain Change From Baseline
Baseline to 6 months
|
-31.17 score on a scale
Standard Deviation 27.39
|
-35.02 score on a scale
Standard Deviation 30.02
|
-30.61 score on a scale
Standard Deviation 24.75
|
|
Visual Analogue Scale (VAS) Pain Change From Baseline
Baseline to 12 months
|
-33.91 score on a scale
Standard Deviation 29.68
|
-36.22 score on a scale
Standard Deviation 28.10
|
-28.14 score on a scale
Standard Deviation 27.81
|
|
Visual Analogue Scale (VAS) Pain Change From Baseline
Baseline to 24 months
|
-35.54 score on a scale
Standard Deviation 29.28
|
—
|
—
|
SECONDARY outcome
Timeframe: 24 monthsPopulation: The Safety (SAF) Population included all participants that received the specified study device with data collected for the outcome and time frame indicated.
Repair failure at 24 months was collected only for participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor. Repair failure was determined by physician diagnosis of recurrent shoulder dislocation, subluxation, and patient symptoms (e.g., pain). In the event of suspected repair failure, MRI or CT scan must confirm the root cause (i.e., intraarticular labrum failure or fixation repair failure) and assess glenoid bone loss. The repair failure rate was defined as the number of participants with confirmed repair failure divided by the total number of participants in the study device group at the 24-month follow-up.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=75 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Repair Failure Rate at 24 Months (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY)
|
—
|
0 proportion of participants
|
—
|
SECONDARY outcome
Timeframe: Baseline, 6 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome, time frame, and treatment group indicated. Participants with discrepancies in MRI and case report form (CRF) data were excluded from analysis. Due to these inconsistencies, only participants with matching MRI and CRF data were analyzed.
Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on acetabular labral condition classification. The number of participants acetabular labral condition was classified as one of the following: * Normal Intact Labrum * Labral Tear / Degeneration
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=45 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
Baseline · Normal Intact Labrum
|
—
|
5 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
Baseline · Labral Tear / Degeneration
|
—
|
32 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
6 months · Normal Intact Labrum
|
—
|
3 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
6 months · Labral Tear / Degeneration
|
—
|
42 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
24 months · Normal Intact Labrum
|
—
|
13 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Acetabular Labral Condition
24 months · Labral Tear / Degeneration
|
—
|
16 Participants
|
—
|
SECONDARY outcome
Timeframe: Baseline, 6 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome, time frame, and treatment group indicated. Participants with discrepancies in MRI and case report form (CRF) data were excluded from analysis. Due to these inconsistencies, only participants with matching MRI and CRF data were analyzed.
Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on joint effusion classification. The number of participants joint effusion was classified as one of the following: * None * Mild * Moderate * Severe
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=10 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · Severe
|
—
|
0 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · None
|
—
|
5 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · Mild
|
—
|
5 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · Moderate
|
—
|
0 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
6 months · Severe
|
—
|
0 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · None
|
—
|
3 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · Mild
|
—
|
3 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · Moderate
|
—
|
0 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
24 months · Severe
|
—
|
0 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · None
|
—
|
9 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · Mild
|
—
|
0 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Joint Effusion
Baseline · Moderate
|
—
|
1 Participants
|
—
|
SECONDARY outcome
Timeframe: Baseline, 6 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome, time frame, and treatment group indicated. Participants with discrepancies in MRI and case report form (CRF) data were excluded from analysis. Due to these inconsistencies, only participants with matching MRI and CRF data were analyzed.
Hip Magnetic Resonance Imagining (MRI) was performed on participants that received the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor to determine anchor absorption/replacement by bone at baseline, 6 months, and 24 months based on the presence of bone marrow edema. The number of participants with bone marrow edema were categorized as 'Absent' or 'Present'.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=10 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
Baseline · Absent
|
—
|
9 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
Baseline · Present
|
—
|
1 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
6 months · Absent
|
—
|
5 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
6 months · Present
|
—
|
5 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
24 months · Absent
|
—
|
4 Participants
|
—
|
|
Anchor Absorption/Replacement by Bone (MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor ONLY): Bone Marrow Edema
24 months · Present
|
—
|
1 Participants
|
—
|
SECONDARY outcome
Timeframe: Baseline to 6 months, 12 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included all shoulder participants enrolled into the study and had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).
The Rowe shoulder score for shoulder instability evaluated using a 3-item instrument completed by the investigator or qualified, delegated study staff. Its questions addressed the categories of shoulder stability (0 to 50 points), motion (0 to 20 points), and function (0 to 30 points). Scores ranged from 0 to 100 with a score of 90-100 points indicating an excellent evaluation, 75-89 points indicating a good evaluation, 51-74 points indicating a fair evaluation, and =\< 50 points indicating a poor evaluation. An increase in Rowe score indicated reduced shoulder instability (i.e., a better outcome) and a decrease indicated worsening instability (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=50 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=35 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=19 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 6 months
|
40.0 score on a scale
Standard Deviation 21.17
|
30.43 score on a scale
Standard Deviation 21.40
|
37.5 score on a scale
Standard Deviation 20.82
|
|
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 12 months
|
43.05 score on a scale
Standard Deviation 21.06
|
34.43 score on a scale
Standard Deviation 22.06
|
44.74 score on a scale
Standard Deviation 28.26
|
|
Rowe Shoulder Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 24 months
|
48.64 score on a scale
Standard Deviation 18.93
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline to 6 months, 12 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included all shoulder participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).
Western Ontario Shoulder Instability Index (WOSI) was a participant completed instrument. Its categories included "physical symptoms", "sports, recreation, work", "pain", "lifestyle", and "emotion", with questions within each category scored from 0 to 100 using a visual analog scale. Scores were combined to produce an overall score that ranged from 0 to 2100 with a score of 0 indicating better shoulder function and 2100 indicating worse shoulder function. A decrease in WOSI score indicated improving shoulder function (i.e., a better outcome) and an increase indicated worsening shoulder function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=49 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=35 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=18 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 6 months
|
-792.94 score on a scale
Standard Deviation 505.37
|
-925.68 score on a scale
Standard Deviation 500.71
|
-719.44 score on a scale
Standard Deviation 393.45
|
|
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 12 months
|
-989.85 score on a scale
Standard Deviation 483.85
|
-988.43 score on a scale
Standard Deviation 453.91
|
-927.06 score on a scale
Standard Deviation 511.32
|
|
Western Ontario Shoulder Instability Index (WOSI) Score Change From Baseline (Shoulder Participants ONLY)
Baseline to 24 months
|
-1110.03 score on a scale
Standard Deviation 447.06
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline to 6 months, 12 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included all shoulder participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).
Constant-Murley Shoulder (CMS) scale assesses four aspects related to shoulder pathology: pain, activities of daily living (ADL), range of motion (ROM), and strength. The total score ranged from 0 to 100, with a higher score indicating better shoulder function. An increase in CMS score indicated improving shoulder function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=43 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=29 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=19 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Baseline to 6 months
|
23.60 score on a scale
Standard Deviation 24.78
|
26.11 score on a scale
Standard Deviation 19.07
|
17.14 score on a scale
Standard Deviation 25.98
|
|
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Baseline to 12 months
|
29.78 score on a scale
Standard Deviation 20.47
|
32.31 score on a scale
Standard Deviation 12.91
|
30.18 score on a scale
Standard Deviation 25.85
|
|
Constant-Murley Shoulder Scale Change From Baseline (Should Participants ONLY)
Baseline to 24 months
|
38.53 score on a scale
Standard Deviation 22.26
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline to 6 months, 12 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included all hip participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).
The Hip Outcome Score Activities of Daily Living (HOS-ADL) subscale consisted of 17 items that addressed specific activities related to hip function. Scores ranged from 0 to 100 with 0 representing the least function and 100 representing the most function. An increase in HOS-ADL score indicated improved hip function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=38 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=37 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=17 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Baseline to 6 months
|
26.20 score on a scale
Standard Deviation 16.93
|
20.03 score on a scale
Standard Deviation 16.29
|
21.11 score on a scale
Standard Deviation 14.44
|
|
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Baseline to 12 months
|
25.91 score on a scale
Standard Deviation 18.50
|
22.19 score on a scale
Standard Deviation 16.88
|
23.00 score on a scale
Standard Deviation 13.20
|
|
Hip Outcome Score Activities of Daily Living (HOS-ADL) Score Change in Baseline (Hip Participants ONLY)
Baseline to 24 months
|
25.95 score on a scale
Standard Deviation 16.71
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline to 6 months, 12 months, and 24 monthsPopulation: The Full Analysis Set (FAS) Population included all hip participants enrolled into the study that had at least one post-baseline visit with data collected for the outcome and time frame indicated. Only the MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor group had a 24-month visit (i.e., MICRORAPTOR™ REGENESORB™ Suture Anchor and MICRORAPTOR™ Knotless PEEK Suture Anchor only conducted 6-month and 12-month visits).
Modified Harris Hip Score (mHHS) is a joint specific score covering domains of pain, function, functional activities, absence of deformity, and hip range of motion. Scores ranged from 0 to 100, with 0 representing worse disability and 100 representing less disability. An increase in mHHS indicated improved hip joint function (i.e., a better outcome) and a decrease indicated worsening function (i.e., a worse outcome). The mean change in score was recorded from baseline to each scheduled post-operative visit at 6 months, 12 months, and 24 months as specified depending on the treatment group.
Outcome measures
| Measure |
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=52 Participants
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=47 Participants
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=28 Participants
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Baseline to 6 months
|
25.88 score on a scale
Standard Deviation 19.56
|
17.28 score on a scale
Standard Deviation 17.23
|
21.54 score on a scale
Standard Deviation 15.76
|
|
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Baseline to 12 months
|
24.56 score on a scale
Standard Deviation 17.40
|
23.60 score on a scale
Standard Deviation 17.50
|
17.79 score on a scale
Standard Deviation 14.35
|
|
Modified Harris Hip Score (mHHS) Change From Baseline (Hip Participants ONLY)
Baseline to 24 months
|
25.05 score on a scale
Standard Deviation 19.01
|
—
|
—
|
Adverse Events
MICRORAPTOR™ REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
MICRORAPTOR™ Knotless PEEK Suture Anchor
Serious adverse events
| Measure |
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=114 participants at risk
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=122 participants at risk
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=61 participants at risk
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
Cardiac disorders
ISCHEMIC HEART DISEASE
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Gastrointestinal disorders
UNSPECIFIED GASTROINTESTINAL PROBLEM
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
ARTHRITIS
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
ANKYLOSIS
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
MUSCLE/TENDON DAMAGE
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
OSSIFICATION
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
UNSPECIFIED MUSCULOSKELETAL PROBLEM
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Skin and subcutaneous tissue disorders
CELLULITIS
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
IMPLANT PAIN
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
INADEQUATE PAIN RELIEF
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
HERNIA
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
PAIN
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
Other adverse events
| Measure |
MICRORAPTOR™ REGENESORB™ Suture Anchor
n=114 participants at risk
Participants receiving the study device: MICRORAPTOR™ REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
n=122 participants at risk
Participants receiving the study device: MICRORAPTOR™ Knotless REGENESORB™ Suture Anchor
|
MICRORAPTOR™ Knotless PEEK Suture Anchor
n=61 participants at risk
Participants receiving the study device: Participants receiving the study device: MICRORAPTOR™ Knotless PEEK Suture Anchor
|
|---|---|---|---|
|
General disorders
HEADACHE
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Nervous system disorders
NERVE DAMAGE
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Nervous system disorders
NEURALGIA
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Nervous system disorders
NUMBNESS
|
1.8%
2/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Immune system disorders
HYPERSENSITIVITY/ALLERGIC REACTION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Cardiac disorders
PERICARDITIS
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMPHYSEMA
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Respiratory, thoracic and mediastinal disorders
RESPIRATORY TRACT INFECTION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Eye disorders
UNSPECIFIED EYE / VISION PROBLEM
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Gastrointestinal disorders
NAUSEA
|
2.6%
3/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Gastrointestinal disorders
UNSPECIFIED GASTROINTESTINAL PROBLEM
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Renal and urinary disorders
MICTURITION URGENCY
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Renal and urinary disorders
URINARY RETENTION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
1.8%
2/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
BONE FRACTURE(S)
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
3.3%
2/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
CRAMP(S) /MUSCLE SPASM(S)
|
1.8%
2/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
DAMAGE TO LIGAMENT(S)
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
JOINT DISLOCATION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
LOSS OF RANGE OF MOTION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
2.5%
3/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
MUSCLE/TENDON DAMAGE
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
NECK PAIN
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
OSSIFICATION
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
TOOTH FRACTURE
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Musculoskeletal and connective tissue disorders
UNSPECIFIED MUSCULOSKELETAL PROBLEM
|
4.4%
5/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
1/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Infections and infestations
ABSCESS
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Skin and subcutaneous tissue disorders
URTICARIA
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
CYST(S)
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Infections and infestations
VIRAL INFECTION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
FALL
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
UNSPECIFIED TISSUE INJURY
|
0.88%
1/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Injury, poisoning and procedural complications
IMPLANT PAIN
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
Investigations
LOW OXYGEN SATURATION
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
INFLAMMATION
|
2.6%
3/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
1.6%
2/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
PAIN
|
9.6%
11/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
8.2%
10/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
3.3%
2/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
CHEST PAIN
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
|
General disorders
SWELLING/ EDEMA
|
0.00%
0/114 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.82%
1/122 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
0.00%
0/61 • Adverse events were collected during surgery to study completion, approximately 12 months. The MICRORAPTOR™ Knotless PEEK Suture Anchor group collected adverse events for an additional 12 months (i.e., adverse events were collected during surgery to approximately 24 months).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period up to 90 days but less than or equal to 180 days from the time submitted to the sponsor for review. Sponsor may delay publication up to 180 days to permit the filing of appropriate patent applications if the sponsor believes any publication contains any information relating to patentable items and cannot extend the embargo.
- Publication restrictions are in place
Restriction type: OTHER